Result of Annual General Meeting
Craven House Capital PLC
04 January 2024
Craven House Capital plc
("Craven House" or the "Company")
Result of Annual General Meeting
Craven House Capital (AIM:CRV) is pleased to announce that all resolutions proposed at its Annual General Meeting were duly passed.
For further information please contact:
|
Craven House Capital Plc Mark Pajak
|
Tel: 0203 286 8130
|
|
SI Capital Broker Nick Emerson |
Tel: 01483 413500 |
|
SPARK Advisory Partners Limited Nominated Adviser Matt Davis |
Tel: 0203 368 3550
|
About Craven House Capital:
The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 31 minutes ago Pharos Energy
- 1 hour ago Galantas Gold Corp.
- 1 hour ago Arrow Exploration Corp. (Cdi)
- 1 hour ago Redx Pharma
- 1 hour ago EPE Special Opportunities Limited (DI)